{
  "doc_id": "603c4e536952d737cd7b84008a9dfac1c2d2a8414117b6ae441f4a359c15f033",
  "chunk_entities": [
    {
      "chunk_id": "5048dcec91ea008051b55e8d8bfc1ab7",
      "entities": [
        {
          "entity_type": "Effect",
          "entity_name": "Modulation",
          "context": "Modulation of monoamine oxidase"
        },
        {
          "entity_type": "Compound",
          "entity_name": "monoamine oxidase",
          "context": "Modulation of monoamine oxidase (MAO) expression"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO",
          "context": "monoamine oxidase (MAO) expression"
        },
        {
          "entity_type": "Disease",
          "entity_name": "neuropsychiatric disorders",
          "context": "expression in neuropsychiatric disorders"
        },
        {
          "entity_type": "Compound",
          "entity_name": "type A MAO",
          "context": "involved in type A MAO expression"
        }
      ]
    },
    {
      "chunk_id": "01cb44bd0d4949513c8a72d4b1a8f176",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "Monoamine oxidase types A",
          "context": "Monoamine oxidase types A and B (MAO-A, MAO-B)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Monoamine oxidase types B",
          "context": "Monoamine oxidase types A and B (MAO-A, MAO-B)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO-A",
          "context": "(MAO-A, MAO-B) regulate"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO-B",
          "context": "(MAO-A, MAO-B) regulate"
        },
        {
          "entity_type": "Compound",
          "entity_name": "monoamine neurotransmitters",
          "context": "levels of monoamine neurotransmitters in the brain"
        },
        {
          "entity_type": "Disease",
          "entity_name": "neuropsychiatric disorders",
          "context": "phenotypes of neuropsychiatric disorders"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Reversible MAO-A inhibitors",
          "context": "Reversible MAO-A inhibitors, such as moclobemide"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO-A",
          "context": "Reversible MAO-A inhibitors"
        },
        {
          "entity_type": "Compound",
          "entity_name": "moclobemide",
          "context": "such as moclobemide and befloxatone"
        },
        {
          "entity_type": "Compound",
          "entity_name": "befloxatone",
          "context": "moclobemide and befloxatone"
        },
        {
          "entity_type": "Disease",
          "entity_name": "emotional disorders",
          "context": "treatment of emotional disorders"
        },
        {
          "entity_type": "Effect",
          "entity_name": "inhibiting the enzymatic degradation",
          "context": "by inhibiting the enzymatic degradation of dopamine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine",
          "context": "degradation of dopamine, serotonin and norepinephrine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "serotonin",
          "context": "dopamine, serotonin and norepinephrine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "norepinephrine",
          "context": "dopamine, serotonin and norepinephrine"
        },
        {
          "entity_type": "Effect",
          "entity_name": "irreversible MAO-B inhibitors",
          "context": "the irreversible MAO-B inhibitors selegiline"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO-B",
          "context": "irreversible MAO-B inhibitors"
        },
        {
          "entity_type": "Compound",
          "entity_name": "selegiline",
          "context": "inhibitors selegiline and rasagiline"
        },
        {
          "entity_type": "Compound",
          "entity_name": "rasagiline",
          "context": "selegiline and rasagiline exert"
        },
        {
          "entity_type": "Effect",
          "entity_name": "neuroprotective effect",
          "context": "exert a neuroprotective effect in Parkinson's"
        },
        {
          "entity_type": "Disease",
          "entity_name": "Parkinson's disease",
          "context": "in Parkinson's and Alzheimer's diseases"
        },
        {
          "entity_type": "Disease",
          "entity_name": "Alzheimer's disease",
          "context": "Parkinson's and Alzheimer's diseases"
        },
        {
          "entity_type": "Effect",
          "entity_name": "inhibition of MAO activity",
          "context": "their inhibition of MAO activity"
        },
        {
          "entity_type": "Compound",
          "entity_name": "selegiline",
          "context": "selegiline and rasagiline protect neuronal cells"
        },
        {
          "entity_type": "Compound",
          "entity_name": "rasagiline",
          "context": "selegiline and rasagiline protect neuronal cells"
        },
        {
          "entity_type": "Effect",
          "entity_name": "protect neuronal cells",
          "context": "selegiline and rasagiline protect neuronal cells"
        },
        {
          "entity_type": "Effect",
          "entity_name": "anti-apoptotic activity",
          "context": "through their anti-apoptotic activity"
        },
        {
          "entity_type": "Effect",
          "entity_name": "induction of pro-survival genes",
          "context": "and induction of pro-survival genes"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO-A",
          "context": "MAO-A activity, but not that of MAO-B"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO-B",
          "context": "that of MAO-B, is implicated"
        },
        {
          "entity_type": "Disease",
          "entity_name": "neurodegenerative disorders",
          "context": "pathophysiology of neurodegenerative disorders"
        },
        {
          "entity_type": "Effect",
          "entity_name": "gene induction",
          "context": "in gene induction by MAO-B inhibitors"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO-B",
          "context": "gene induction by MAO-B inhibitors"
        },
        {
          "entity_type": "Compound",
          "entity_name": "selegiline",
          "context": "selegiline and rasagiline increase MAO-"
        },
        {
          "entity_type": "Compound",
          "entity_name": "rasagiline",
          "context": "selegiline and rasagiline increase MAO-"
        }
      ]
    },
    {
      "chunk_id": "a2aca55a54c81444d8e0aa4e11b2af3a",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "mRNA",
          "context": "A mRNA, protein, and enzyme activity levels."
        },
        {
          "entity_type": "Compound",
          "entity_name": "protein",
          "context": "A mRNA, protein, and enzyme activity levels."
        },
        {
          "entity_type": "Compound",
          "entity_name": "enzyme",
          "context": "A mRNA, protein, and enzyme activity levels."
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO",
          "context": "each MAO subtype exerts effects"
        },
        {
          "entity_type": "Compound",
          "entity_name": "isoenzyme",
          "context": "activity of the other isoenzyme."
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO-A",
          "context": "The roles of MAO-A and -B"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO-B",
          "context": "The roles of MAO-A and -B"
        },
        {
          "entity_type": "Compound",
          "entity_name": "inhibitors",
          "context": "type-specificity\" of their inhibitors"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Mao-a",
          "context": "Mao-a expression, in particular,"
        },
        {
          "entity_type": "Disease",
          "entity_name": "pathogenesis",
          "context": "may be implicated in pathogenesis"
        },
        {
          "entity_type": "Disease",
          "entity_name": "neuropsychiatric disorders",
          "context": "phenotypes in neuropsychiatric disorders."
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO-A",
          "context": "MAO-A expression is modified"
        },
        {
          "entity_type": "Compound",
          "entity_name": "mao polymorphisms",
          "context": "modified by mao polymorphisms"
        },
        {
          "entity_type": "Effect",
          "entity_name": "transcriptional efficiency",
          "context": "affecting its transcriptional efficiency"
        },
        {
          "entity_type": "Compound",
          "entity_name": "parkin",
          "context": "polymorphism of parkin"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Sirt1",
          "context": "polymorphism of parkin, Sirt1"
        },
        {
          "entity_type": "Compound",
          "entity_name": "FOXO",
          "context": "Sirt1, FOXO"
        },
        {
          "entity_type": "Compound",
          "entity_name": "microRNA",
          "context": "FOXO, microRNA"
        },
        {
          "entity_type": "Compound",
          "entity_name": "presenilin-1",
          "context": "microRNA, presenilin-1, and other regulatory proteins."
        },
        {
          "entity_type": "Compound",
          "entity_name": "regulatory proteins",
          "context": "other regulatory proteins."
        },
        {
          "entity_type": "Compound",
          "entity_name": "mao-a polymorphisms",
          "context": "children with mao-a polymorphisms"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO-A",
          "context": "Low MAO-A activity may increase"
        },
        {
          "entity_type": "Compound",
          "entity_name": "serotonin",
          "context": "increase the levels of serotonin and norepinephrine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "norepinephrine",
          "context": "serotonin and norepinephrine, resulting in disturbed neurotransmitter system development"
        },
        {
          "entity_type": "Compound",
          "entity_name": "neurotransmitter",
          "context": "disturbed neurotransmitter system development"
        },
        {
          "entity_type": "Disease",
          "entity_name": "disturbed neurotransmitter system development",
          "context": "disturbed neurotransmitter system development and behavior."
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO-A",
          "context": "regulation of MAO-A expression"
        },
        {
          "entity_type": "Effect",
          "entity_name": "neuronal survival",
          "context": "regulation of neuronal survival and death."
        },
        {
          "entity_type": "Effect",
          "entity_name": "neuronal death",
          "context": "neuronal survival and death."
        }
      ]
    },
    {
      "chunk_id": "6246d5095f68adaec8749492d1115a02",
      "entities": [
        {
          "entity_type": "Disease",
          "entity_name": "Alzheimer's disease",
          "context": "ADAlzheimer's disease"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Brain-derived neurotrophic factor",
          "context": "BDNFBrain-derived neurotrophic factor"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Dopamine",
          "context": "DADopamine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Disrupted-in-schizophrenia 1",
          "context": "DISC1Disrupted-in-schizophrenia 1"
        }
      ]
    },
    {
      "chunk_id": "95ca29924c0669cd11da666946d978dd",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "MAO-A",
          "context": "characteristics of both MAO-A and -B"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO-B",
          "context": "characteristics of both MAO-A and -B"
        },
        {
          "entity_type": "Compound",
          "entity_name": "proteins",
          "context": "composed of different proteins"
        },
        {
          "entity_type": "Compound",
          "entity_name": "amino acid sequences",
          "context": "70 % identical amino acid sequences"
        },
        {
          "entity_type": "Compound",
          "entity_name": "FAD",
          "context": "same coenzyme, FAD, is bound"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cysteine",
          "context": "bound to the cysteine of a pentapeptide sequence"
        },
        {
          "entity_type": "Compound",
          "entity_name": "pentapeptide sequence",
          "context": "cysteine of a pentapeptide sequence, Ser-Gly-Gly-Cys-Tyr"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Ser-Gly-Gly-Cys-Tyr",
          "context": "pentapeptide sequence, Ser-Gly-Gly-Cys-Tyr"
        },
        {
          "entity_type": "Compound",
          "entity_name": "thioester linkage",
          "context": "via a covalent thioester linkage"
        }
      ]
    },
    {
      "chunk_id": "c9c0fd206a290df383eab2202e5029eb",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "hydrogen peroxide",
          "context": "increased hydrogen peroxide levels"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO-B",
          "context": "enhanced MAO-B activity"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO-A",
          "context": "not that of MAO-A"
        },
        {
          "entity_type": "Disease",
          "entity_name": "Parkinson's Disease",
          "context": "pathogenic factor in PD"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO-B inhibitors",
          "context": "development of MAO-B inhibitors"
        },
        {
          "entity_type": "Effect",
          "entity_name": "disease-modifying",
          "context": "disease-modifying agents"
        },
        {
          "entity_type": "Compound",
          "entity_name": "selegiline",
          "context": "selegiline and rasagiline"
        },
        {
          "entity_type": "Compound",
          "entity_name": "rasagiline",
          "context": "selegiline and rasagiline"
        },
        {
          "entity_type": "Compound",
          "entity_name": "(1R)-N-prop-2-ynyl-2,3-dihydro-1H-amine",
          "context": "rasagiline [(1R)-N-prop-2-ynyl-2,3-dihydro-1H-amine]"
        },
        {
          "entity_type": "Effect",
          "entity_name": "neuroprotection",
          "context": "protect neuronal cells"
        }
      ]
    },
    {
      "chunk_id": "318b211536ce9958c5437db13b3d16b3",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "MAO (Monoamine Oxidase)",
          "context": "The role of MAO itself"
        },
        {
          "entity_type": "Effect",
          "entity_name": "neuronal death",
          "context": "MAO itself in neuronal death"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO (Monoamine Oxidase)",
          "context": "role of MAO isomers"
        },
        {
          "entity_type": "Effect",
          "entity_name": "neuronal death",
          "context": "regulation of neuronal death"
        },
        {
          "entity_type": "Effect",
          "entity_name": "survival",
          "context": "neuronal death and survival"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO (Monoamine Oxidase)",
          "context": "involvement of MAO in neuroprotection"
        },
        {
          "entity_type": "Effect",
          "entity_name": "neuroprotection",
          "context": "MAO in neuroprotection"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO-B inhibitors",
          "context": "neuroprotection by MAO-B inhibitors"
        },
        {
          "entity_type": "Effect",
          "entity_name": "anti-apoptotic",
          "context": "induction of anti-apoptotic"
        },
        {
          "entity_type": "Effect",
          "entity_name": "pro-survival",
          "context": "pro-survival genes"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO-B inhibitors",
          "context": "The MAO-B inhibitors rasagiline and selegiline"
        },
        {
          "entity_type": "Compound",
          "entity_name": "rasagiline",
          "context": "MAO-B inhibitors rasagiline"
        },
        {
          "entity_type": "Compound",
          "entity_name": "selegiline",
          "context": "rasagiline and selegiline"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PEA (Phenethylamine)",
          "context": "preferential MAO-B substrate PEA"
        },
        {
          "entity_type": "Effect",
          "entity_name": "mao-a expression",
          "context": "induce mao-a expression"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO-B (Monoamine Oxidase B)",
          "context": "MAO-B activity may modify"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO-A (Monoamine Oxidase A)",
          "context": "function of MAO-A"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO (Monoamine Oxidase)",
          "context": "deficient MAO expression"
        },
        {
          "entity_type": "Disease",
          "entity_name": "antisocial behaviors",
          "context": "risk for antisocial behaviors"
        },
        {
          "entity_type": "Disease",
          "entity_name": "neuropsychiatric disorders",
          "context": "phenotypes of neuropsychiatric disorders"
        }
      ]
    },
    {
      "chunk_id": "fde0a9ff3e2bebda7e149952ff29503e",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "MAO-B",
          "context": "CNS MAO-B activity"
        },
        {
          "entity_type": "Disease",
          "entity_name": "neurodegeneration",
          "context": "role in neurodegeneration"
        },
        {
          "entity_type": "Compound",
          "entity_name": "ROS",
          "context": "ROS production"
        },
        {
          "entity_type": "Compound",
          "entity_name": "neurotoxins",
          "context": "and neurotoxins"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO-B",
          "context": "MAO-B-deficient mice"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MPTP",
          "context": "resistant to MPTP toxicity"
        },
        {
          "entity_type": "Effect",
          "entity_name": "resistant to toxicity",
          "context": "resistant to MPTP toxicity"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO-B",
          "context": "MAO-B expression"
        },
        {
          "entity_type": "Effect",
          "entity_name": "increased sensitivity",
          "context": "increased the sensitivity"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MPTP",
          "context": "sensitivity to MPTP"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO-A",
          "context": "express only MAO-A"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO-B",
          "context": "role of MAO-B"
        },
        {
          "entity_type": "Effect",
          "entity_name": "cytotoxicity",
          "context": "in the cytotoxicity"
        },
        {
          "entity_type": "Compound",
          "entity_name": "NE",
          "context": "a NE toxin"
        },
        {
          "entity_type": "Compound",
          "entity_name": "N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine",
          "context": "N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "DSP-4",
          "context": "N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-HT",
          "context": "a 5-HT toxin"
        },
        {
          "entity_type": "Compound",
          "entity_name": "3,4-methylenedioxyamphetamine",
          "context": "3,4-methylenedioxyamphetamine (MDMA, \u201cecstasy\u201d)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MDMA",
          "context": "3,4-methylenedioxyamphetamine (MDMA, \u201cecstasy\u201d)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO-B",
          "context": "MAO-B deficient mice"
        },
        {
          "entity_type": "Compound",
          "entity_name": "DSP-4",
          "context": "while DSP-4 markedly depleted NE"
        },
        {
          "entity_type": "Effect",
          "entity_name": "depleted",
          "context": "markedly depleted NE"
        },
        {
          "entity_type": "Compound",
          "entity_name": "NE",
          "context": "depleted NE"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO-B",
          "context": "MAO-B knockout mice"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO-B",
          "context": "MAO-B was not involved"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MDMA",
          "context": "MDMA caused massive loss"
        },
        {
          "entity_type": "Effect",
          "entity_name": "massive loss",
          "context": "caused massive loss"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-HT",
          "context": "loss of both 5-HT"
        },
        {
          "entity_type": "Compound",
          "entity_name": "DA",
          "context": "and DA"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO-B",
          "context": "MAO-B deficient mice"
        },
        {
          "entity_type": "Compound",
          "entity_name": "DA",
          "context": "DA depletion"
        },
        {
          "entity_type": "Effect",
          "entity_name": "depletion",
          "context": "DA depletion"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO-B",
          "context": "MAO-B may also be involved"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MDMA",
          "context": "MDMA-induced loss"
        },
        {
          "entity_type": "Effect",
          "entity_name": "loss",
          "context": "MDMA-induced loss"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-HT",
          "context": "loss of 5-HT"
        },
        {
          "entity_type": "Effect",
          "entity_name": "prevented",
          "context": "can be prevented"
        },
        {
          "entity_type": "Compound",
          "entity_name": "selegiline",
          "context": "prevented by selegiline"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO-B",
          "context": "MAO-B knockdown"
        },
        {
          "entity_type": "Effect",
          "entity_name": "knockdown",
          "context": "MAO-B knockdown"
        },
        {
          "entity_type": "Compound",
          "entity_name": "antisense oligonucleotide",
          "context": "an antisense oligonucleotide"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO-B",
          "context": "role of MAO-B"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-HT",
          "context": "5-HT depletion"
        },
        {
          "entity_type": "Effect",
          "entity_name": "depletion",
          "context": "5-HT depletion"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MDMA",
          "context": "MDMA is a potent MAO-A inhibitor"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO-A",
          "context": "potent MAO-A inhibitor"
        },
        {
          "entity_type": "Effect",
          "entity_name": "inhibitor",
          "context": "MAO-A inhibitor"
        },
        {
          "entity_type": "Compound",
          "entity_name": "[^{3}\text{H}-methyl]-L-deprenyl",
          "context": "binding of [^{3}\text{H}-methyl]-L-deprenyl"
        },
        {
          "entity_type": "Effect",
          "entity_name": "abolished",
          "context": "was abolished"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO-B",
          "context": "MAO-B knockout mice"
        },
        {
          "entity_type": "Effect",
          "entity_name": "protection",
          "context": "the protection afforded"
        },
        {
          "entity_type": "Compound",
          "entity_name": "selegiline",
          "context": "afforded by selegiline"
        },
        {
          "entity_type": "Disease",
          "entity_name": "ischemic infarction",
          "context": "in ischemic infarction"
        },
        {
          "entity_type": "Disease",
          "entity_name": "cerebral edema",
          "context": "cerebral edema"
        },
        {
          "entity_type": "Disease",
          "entity_name": "neurological impairment",
          "context": "and neurological impairment"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO isoenzymes",
          "context": "role of MAO isoenzymes"
        },
        {
          "entity_type": "Disease",
          "entity_name": "neuronal death",
          "context": "in neuronal death"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO-A",
          "context": "MAO-A knockout animals"
        },
        {
          "entity_type": "Disease",
          "entity_name": "neurological insults",
          "context": "other neurological and neurotoxic insults"
        },
        {
          "entity_type": "Disease",
          "entity_name": "neurotoxic insults",
          "context": "and neurotoxic insults"
        }
      ]
    },
    {
      "chunk_id": "9f91335a2e5b6a7ba972c0d0e163329c",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "\\alpha-synuclein",
          "context": "encoding \\alpha-synuclein (PARK1)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "parkin",
          "context": "encoding ... parkin (PARK2)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "ubiquitin-C-hydrolase-L1",
          "context": "ubiquitin-C-hydrolase-L1 (Uch-L1, PARK5)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PINK-1",
          "context": "PINK-1 (PARK6)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "DJ-1",
          "context": "DJ-1 (PARK7)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "LRRK2",
          "context": "and LRRK2"
        },
        {
          "entity_type": "Disease",
          "entity_name": "PD",
          "context": "familial form of PD"
        },
        {
          "entity_type": "Disease",
          "entity_name": "nigrostriatal DA neuronal degeneration",
          "context": "nigrostriatal DA neuronal degeneration in idiopathic PD"
        },
        {
          "entity_type": "Disease",
          "entity_name": "idiopathic PD",
          "context": "neuronal degeneration in idiopathic PD"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Parkin",
          "context": "Parkin, a protein-ubiquitin-E3 ligase"
        },
        {
          "entity_type": "Compound",
          "entity_name": "protein-ubiquitin-E3 ligase",
          "context": "Parkin, a protein-ubiquitin-E3 ligase"
        },
        {
          "entity_type": "Compound",
          "entity_name": "ubiquitin-proteasome system (UPS)",
          "context": "for the ubiquitin-proteasome system (UPS)"
        },
        {
          "entity_type": "Effect",
          "entity_name": "degeneration of DA neurons",
          "context": "causes selective degeneration of DA neurons"
        },
        {
          "entity_type": "Effect",
          "entity_name": "accumulation of \\alpha-synuclein",
          "context": "accumulation of \\alpha-synuclein"
        },
        {
          "entity_type": "Compound",
          "entity_name": "\\alpha-synuclein",
          "context": "accumulation of \\alpha-synuclein"
        },
        {
          "entity_type": "Disease",
          "entity_name": "Lewy bodies",
          "context": "component of Lewy bodies"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO",
          "context": "MAO transcription is down-regulated"
        },
        {
          "entity_type": "Effect",
          "entity_name": "down-regulated",
          "context": "MAO transcription is down-regulated by parkin"
        },
        {
          "entity_type": "Compound",
          "entity_name": "parkin",
          "context": "down-regulated by parkin"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO-B",
          "context": "MAO-B activity in parkin-knockout mice is increased"
        },
        {
          "entity_type": "Effect",
          "entity_name": "increased",
          "context": "MAO-B activity ... is increased"
        },
        {
          "entity_type": "Compound",
          "entity_name": "DOPAC",
          "context": "elevated DOPAC levels"
        },
        {
          "entity_type": "Effect",
          "entity_name": "elevated",
          "context": "elevated DOPAC levels"
        },
        {
          "entity_type": "Compound",
          "entity_name": "parkin",
          "context": "parkin transfection decreased the MAO-B mRNA"
        },
        {
          "entity_type": "Effect",
          "entity_name": "decreased",
          "context": "parkin transfection decreased the MAO-B mRNA"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO-B",
          "context": "decreased the MAO-B mRNA"
        },
        {
          "entity_type": "Effect",
          "entity_name": "ubiquitination",
          "context": "increase the ubiquitination and degradation of MAO-A"
        },
        {
          "entity_type": "Effect",
          "entity_name": "degradation",
          "context": "ubiquitination and degradation of MAO-A"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO-A",
          "context": "degradation of MAO-A"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO",
          "context": "MAO expression was increased significantly"
        },
        {
          "entity_type": "Effect",
          "entity_name": "increased",
          "context": "MAO expression was increased significantly"
        },
        {
          "entity_type": "Disease",
          "entity_name": "PD",
          "context": "derived from PD patients"
        },
        {
          "entity_type": "Compound",
          "entity_name": "parkin",
          "context": "exon 4 in parkin"
        },
        {
          "entity_type": "Compound",
          "entity_name": "parkin",
          "context": "parkin suppresses MAO expression"
        },
        {
          "entity_type": "Effect",
          "entity_name": "suppresses",
          "context": "parkin suppresses MAO expression"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO",
          "context": "suppresses MAO expression"
        },
        {
          "entity_type": "Effect",
          "entity_name": "impairs",
          "context": "impairs the UPS"
        },
        {
          "entity_type": "Compound",
          "entity_name": "UPS",
          "context": "impairs the UPS"
        },
        {
          "entity_type": "Effect",
          "entity_name": "up-regulates",
          "context": "up-regulates MAO levels"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO",
          "context": "up-regulates MAO levels"
        },
        {
          "entity_type": "Effect",
          "entity_name": "DA oxidation",
          "context": "increasing DA oxidation"
        },
        {
          "entity_type": "Effect",
          "entity_name": "cell death",
          "context": "inducing cell death"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO-B",
          "context": "elevated MAO-B levels decreased the ability"
        },
        {
          "entity_type": "Effect",
          "entity_name": "decreased",
          "context": "MAO-B levels decreased the ability"
        },
        {
          "entity_type": "Compound",
          "entity_name": "parkin",
          "context": "ability of parkin to clear damaged mitochondria"
        },
        {
          "entity_type": "Effect",
          "entity_name": "clear damaged mitochondria",
          "context": "parkin to clear damaged mitochondria"
        }
      ]
    },
    {
      "chunk_id": "4b1b9542b0a6d77eaeeba301f9725ec9",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "MAO-B",
          "context": "role of MAO-B in neuronal death"
        },
        {
          "entity_type": "Effect",
          "entity_name": "neuronal death",
          "context": "role of MAO-B in neuronal death"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Selegiline",
          "context": "labeled 'Selegiline, rasagiline'"
        },
        {
          "entity_type": "Compound",
          "entity_name": "rasagiline",
          "context": "labeled 'Selegiline, rasagiline'"
        },
        {
          "entity_type": "Effect",
          "entity_name": "inhibition",
          "context": "indicating inhibition"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Monoamine",
          "context": "boxes for 'Monoamine'"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MPTP",
          "context": "boxes for 'Monoamine' and 'MPTP'"
        },
        {
          "entity_type": "Compound",
          "entity_name": "H2O2",
          "context": "box for 'H2O2'"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Oxidative stress",
          "context": "labeled 'Oxidative stress'"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Cell death",
          "context": "pointing to 'Cell death'"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Parkin",
          "context": "box for 'Parkin'"
        },
        {
          "entity_type": "Compound",
          "entity_name": "ERRs",
          "context": "box for 'ERRs'"
        },
        {
          "entity_type": "Effect",
          "entity_name": "mutation",
          "context": "'Parkin KO, mutation'"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MPP+",
          "context": "box for 'MPP+'"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Apoptosis",
          "context": "labeled 'Apoptosis'"
        }
      ]
    },
    {
      "chunk_id": "9b546c4efee228346b716b41e7264cb9",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "MAO-B",
          "context": "role of MAO-B in neuronal function"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO-B inhibitors",
          "context": "whether MAO-B inhibitors are truly type-specific"
        },
        {
          "entity_type": "Effect",
          "entity_name": "neuronal function",
          "context": "role of MAO-B in neuronal function"
        },
        {
          "entity_type": "Effect",
          "entity_name": "death",
          "context": "neuronal function and death"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO inhibitors",
          "context": "Type-specificity of MAO inhibitors"
        },
        {
          "entity_type": "Compound",
          "entity_name": "rasagiline",
          "context": "rasagiline, for instance, also binds to MAO-A"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO-A",
          "context": "binds to MAO-A and inhibits its enzymatic activity"
        },
        {
          "entity_type": "Effect",
          "entity_name": "inhibits its enzymatic activity",
          "context": "inhibits its enzymatic activity in vitro"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "9.7 \u00b5M",
          "context": "inhibitor constant (K_i) = 9.7 \u00b5M"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "0.7 \u00b5M",
          "context": "for MAO-B (K_i = 0.7 \u00b5M)"
        },
        {
          "entity_type": "Effect",
          "entity_name": "irreversibly inactivates",
          "context": "rasagiline irreversibly inactivates both MAO-A and MAO-B"
        },
        {
          "entity_type": "Compound",
          "entity_name": "flavin cofactor",
          "context": "covalent adduct with the flavin cofactor"
        },
        {
          "entity_type": "Compound",
          "entity_name": "aminoindan",
          "context": "aminoindan, a rasagiline metabolite"
        },
        {
          "entity_type": "Effect",
          "entity_name": "inhibits both isoenzymes",
          "context": "inhibits both isoenzymes, but does not covalently bind the cofactor"
        }
      ]
    },
    {
      "chunk_id": "5f8a64223e11d75b1ed65dddec0a9b2f",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "MAO-B inhibitors",
          "context": "Specific MAO-B inhibitors also suppress MAO-A activity"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO-A",
          "context": "Specific MAO-B inhibitors also suppress MAO-A activity"
        },
        {
          "entity_type": "Effect",
          "entity_name": "suppress MAO-A activity",
          "context": "MAO-B inhibitors also suppress MAO-A activity"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "higher doses",
          "context": "at the higher doses in vivo"
        },
        {
          "entity_type": "Effect",
          "entity_name": "inhibition of MAO-A and -B",
          "context": "The inhibition of MAO-A and -B in the brain"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO-B",
          "context": "The inhibition of MAO-A and -B in the brain"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-HT",
          "context": "either 5-HT (MAO-A) or PEA (MAO-B)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PEA",
          "context": "either 5-HT (MAO-A) or PEA (MAO-B)"
        },
        {
          "entity_type": "Effect",
          "entity_name": "reduced MAO-B activity",
          "context": "MAO-B activity in the rat striatum was reduced by more than 90 %"
        },
        {
          "entity_type": "Compound",
          "entity_name": "selegiline",
          "context": "single administration of selegiline (2.5 mg/kg body weight)"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "2.5 mg/kg body weight",
          "context": "selegiline (2.5 mg/kg body weight)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "rasagiline",
          "context": "or rasagiline (1 mg/kg)"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "1 mg/kg",
          "context": "rasagiline (1 mg/kg)"
        },
        {
          "entity_type": "Effect",
          "entity_name": "lower MAO-A activity",
          "context": "MAO-A activity was also 40 % lower"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "5 mg/kg",
          "context": "higher dose of selegiline (5 mg/kg)"
        },
        {
          "entity_type": "Effect",
          "entity_name": "inhibited MAO-A activity",
          "context": "inhibited MAO-A activity in the rat brain by 85"
        },
        {
          "entity_type": "Effect",
          "entity_name": "inhibited MAO-B activity",
          "context": "MAO-B by 99.9 %"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "0.25 mg/kg",
          "context": "selegiline (0.25 mg/kg)"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "0.05 mg/kg",
          "context": "rasagiline (0.05 mg/kg)"
        },
        {
          "entity_type": "Effect",
          "entity_name": "reduced MAO-A activity",
          "context": "MAO-A activity was reduced by 40 and 15 %"
        },
        {
          "entity_type": "Effect",
          "entity_name": "abolished MAO-B activity",
          "context": "MAO-B activity was almost totally abolished"
        },
        {
          "entity_type": "Compound",
          "entity_name": "clorgyline",
          "context": "clorgyline (0.2 mg/kg) inhibited MAO-A activity"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "0.2 mg/kg",
          "context": "clorgyline (0.2 mg/kg)"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "0.1 mg/kg",
          "context": "rasagiline (0.1 mg/kg, 7 days)"
        },
        {
          "entity_type": "Effect",
          "entity_name": "selectively inhibited brain MAO-B activity",
          "context": "selectively inhibited brain MAO-B activity by 80 %"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "0.5 mg/kg",
          "context": "at 0.5 mg/kg also inhibited MAO-A"
        },
        {
          "entity_type": "Effect",
          "entity_name": "MAO type-specificity",
          "context": "influence the ... MAO type-specificity"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Zydis Selegiline",
          "context": "confirmed for 'Zydis Selegiline' (buccal absorption)"
        }
      ]
    },
    {
      "chunk_id": "00c401e57adb7ae34c3ed6f8519e8476",
      "entities": [
        {
          "entity_type": "Effect",
          "entity_name": "neuroprotection",
          "context": "underlying neuroprotection"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Selegiline",
          "context": "Selegiline and rasagiline suppress"
        },
        {
          "entity_type": "Compound",
          "entity_name": "rasagiline",
          "context": "Selegiline and rasagiline suppress"
        },
        {
          "entity_type": "Effect",
          "entity_name": "suppress mitochondrial death signal pathways",
          "context": "rasagiline suppress mitochondrial death signal pathways"
        },
        {
          "entity_type": "Effect",
          "entity_name": "induce pro-survival genes",
          "context": "induce pro-survival genes"
        },
        {
          "entity_type": "Effect",
          "entity_name": "anti-apoptotic",
          "context": "anti-apoptotic Bcl-2 protein family"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Bcl-2",
          "context": "anti-apoptotic Bcl-2 protein family"
        },
        {
          "entity_type": "Effect",
          "entity_name": "neurotrophic factors",
          "context": "of neurotrophic factors"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO-A",
          "context": "MAO-A mediated Bcl-2 induction"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Bcl-2 induction",
          "context": "MAO-A mediated Bcl-2 induction"
        },
        {
          "entity_type": "Compound",
          "entity_name": "rasagiline",
          "context": "Bcl-2 induction by rasagiline"
        },
        {
          "entity_type": "Effect",
          "entity_name": "suppressed by knockdown of MAO-A expression",
          "context": "an effect suppressed by knockdown of MAO-A expression"
        },
        {
          "entity_type": "Compound",
          "entity_name": "siRNA",
          "context": "expression with siRNA"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Rasagiline",
          "context": "Rasagiline neither induce Bcl-2"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Bcl-2",
          "context": "induce Bcl-2 in MAO-B"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO-B",
          "context": "MAO-B overexpressed SH-SY5Y cells"
        },
        {
          "entity_type": "Disease",
          "entity_name": "human colon carcinoma",
          "context": "human colon carcinoma Caco-2 cells"
        },
        {
          "entity_type": "Effect",
          "entity_name": "inhibitor",
          "context": "by this inhibitor"
        },
        {
          "entity_type": "Compound",
          "entity_name": "rasagiline",
          "context": "concentration of rasagiline that induces"
        },
        {
          "entity_type": "Effect",
          "entity_name": "induces Bcl-2",
          "context": "rasagiline that induces Bcl-2"
        },
        {
          "entity_type": "Effect",
          "entity_name": "inhibits MAO-A",
          "context": "than that inhibits MAO-A"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO-A",
          "context": "inhibits MAO-A"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "picomolar",
          "context": "(picomolar rather than micromolar"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "micromolar",
          "context": "rather than micromolar"
        }
      ]
    },
    {
      "chunk_id": "705b7fbe2e6a2602d4a117b3f03d0ee4",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "rasagiline",
          "context": "rasagiline and selegiline"
        },
        {
          "entity_type": "Compound",
          "entity_name": "selegiline",
          "context": "rasagiline and selegiline"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Induction of pro-survival genes",
          "context": "Induction of pro-survival genes by rasagiline"
        },
        {
          "entity_type": "Compound",
          "entity_name": "rasagiline",
          "context": "administration of rasagiline to Japanese monkeys"
        },
        {
          "entity_type": "Compound",
          "entity_name": "glial cell-derived neurotrophic factor (GDNF)",
          "context": "glial cell-derived neurotrophic factor (GDNF)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "brain-derived neurotrophic factor (BDNF)",
          "context": "brain-derived neurotrophic factor (BDNF)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "neurotrophic factor-3 (NT-3)",
          "context": "neurotrophic factor-3 (NT-3)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "nerve-growth factor (NGF)",
          "context": "nerve-growth factor (NGF)"
        },
        {
          "entity_type": "Effect",
          "entity_name": "increased the cerebrospinal fluid (CSF) levels of the neurotrophins",
          "context": "increased the cerebrospinal fluid (CSF) levels of the neurotrophins"
        }
      ]
    },
    {
      "chunk_id": "7f54260337db3b81665e79e587b93f55",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "selegiline",
          "context": "Clinical trials of selegiline and rasagiline"
        },
        {
          "entity_type": "Compound",
          "entity_name": "rasagiline",
          "context": "selegiline and rasagiline in PD patients"
        },
        {
          "entity_type": "Disease",
          "entity_name": "PD",
          "context": "in PD patients"
        },
        {
          "entity_type": "Effect",
          "entity_name": "symptomatic results",
          "context": "achieved beneficial symptomatic results"
        },
        {
          "entity_type": "Effect",
          "entity_name": "disease progression",
          "context": "reverse disease progression"
        },
        {
          "entity_type": "Effect",
          "entity_name": "MAO inhibition",
          "context": "contribution of MAO inhibition to improvement"
        },
        {
          "entity_type": "Effect",
          "entity_name": "enzyme activity",
          "context": "comparing the enzyme activity"
        },
        {
          "entity_type": "Effect",
          "entity_name": "clinical benefit",
          "context": "degree of clinical benefit"
        }
      ]
    },
    {
      "chunk_id": "c942913f715d65e1b33841011f70f44f",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "Rasagiline",
          "context": "Rasagiline and selegiline may bind to MAO"
        },
        {
          "entity_type": "Compound",
          "entity_name": "selegiline",
          "context": "Rasagiline and selegiline may bind to MAO"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO",
          "context": "may bind to MAO at the sites"
        },
        {
          "entity_type": "Compound",
          "entity_name": "imidazoline",
          "context": "binding site for imidazoline has been identified"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO-B",
          "context": "identified on MAO-B"
        },
        {
          "entity_type": "Compound",
          "entity_name": "I_2 ligands",
          "context": "I_2 ligands bind and inhibit MAO-A and -B"
        },
        {
          "entity_type": "Effect",
          "entity_name": "inhibit",
          "context": "I_2 ligands bind and inhibit MAO-A and -B"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO-A",
          "context": "inhibit MAO-A and -B"
        },
        {
          "entity_type": "Compound",
          "entity_name": "I_1 receptor",
          "context": "The I_1 receptor was identified as a target"
        },
        {
          "entity_type": "Compound",
          "entity_name": "S-enantiomer of rasagiline",
          "context": "target for the S-enantiomer of rasagiline"
        },
        {
          "entity_type": "Compound",
          "entity_name": "TV1022",
          "context": "rasagiline, TV1022, via which the inhibitor"
        },
        {
          "entity_type": "Effect",
          "entity_name": "increased the levels of phosphorylated p42 and p44 MAPK",
          "context": "inhibitor increased the levels of phosphorylated p42 and p44 MAPK"
        },
        {
          "entity_type": "Compound",
          "entity_name": "phosphorylated p42 MAPK",
          "context": "levels of phosphorylated p42 and p44 MAPK"
        },
        {
          "entity_type": "Compound",
          "entity_name": "p44 MAPK",
          "context": "levels of phosphorylated p42 and p44 MAPK"
        },
        {
          "entity_type": "Effect",
          "entity_name": "protected",
          "context": "and protected the cells from serum deprivation-induced apoptosis"
        },
        {
          "entity_type": "Disease",
          "entity_name": "serum deprivation-induced apoptosis",
          "context": "protected the cells from serum deprivation-induced apoptosis"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-HT",
          "context": "5-HT inhibited the specific binding of TV1022"
        },
        {
          "entity_type": "Effect",
          "entity_name": "inhibited",
          "context": "5-HT inhibited the specific binding of TV1022"
        },
        {
          "entity_type": "Effect",
          "entity_name": "increases pro-survival Bcl-2",
          "context": "increases pro-survival Bcl-2 and neurotrophic factor levels"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Bcl-2",
          "context": "pro-survival Bcl-2 and neurotrophic factor levels"
        },
        {
          "entity_type": "Compound",
          "entity_name": "neurotrophic factor",
          "context": "and neurotrophic factor levels"
        }
      ]
    },
    {
      "chunk_id": "258a1f7693b7e91340a8a04afb0dfb79",
      "entities": [
        {
          "entity_type": "Effect",
          "entity_name": "Induction of MAO-A expression",
          "context": "Induction of MAO-A expression by MAO-B inhibitors"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO-B inhibitors",
          "context": "MAO-A expression by MAO-B inhibitors plus substrate"
        },
        {
          "entity_type": "Compound",
          "entity_name": "substrate",
          "context": "MAO-B inhibitors plus substrate"
        }
      ]
    },
    {
      "chunk_id": "533b3d5d9977ea702d692d07fc3f6351",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "MAO-A",
          "context": "MAO-A expression"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Sp1",
          "context": "transcription factor Sp1"
        },
        {
          "entity_type": "Compound",
          "entity_name": "R1",
          "context": "transcription repressor R1"
        },
        {
          "entity_type": "Compound",
          "entity_name": "RAM2",
          "context": "R1 (RAM2/CDCA7L/JPO2)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "CDCA7L",
          "context": "R1 (RAM2/CDCA7L/JPO2)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "JPO2",
          "context": "R1 (RAM2/CDCA7L/JPO2)"
        }
      ]
    },
    {
      "chunk_id": "ca68592d53d2ad98151fad086dc93a1f",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "alcohol",
          "context": "blood alcohol content was positively correlated"
        },
        {
          "entity_type": "Effect",
          "entity_name": "neuronal dysfunction",
          "context": "involved in neuronal dysfunction and death"
        },
        {
          "entity_type": "Effect",
          "entity_name": "death",
          "context": "neuronal dysfunction and death in alcoholism"
        },
        {
          "entity_type": "Disease",
          "entity_name": "alcoholism",
          "context": "death in alcoholism"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Ethanol",
          "context": "Ethanol also induced the nuclear translocation"
        },
        {
          "entity_type": "Effect",
          "entity_name": "cell death",
          "context": "leading to cell death that could be prevented"
        },
        {
          "entity_type": "Compound",
          "entity_name": "rasagiline",
          "context": "prevented by rasagiline and selegiline"
        },
        {
          "entity_type": "Compound",
          "entity_name": "selegiline",
          "context": "prevented by rasagiline and selegiline"
        },
        {
          "entity_type": "Compound",
          "entity_name": "glucocorticoid",
          "context": "response elements for glucocorticoid"
        },
        {
          "entity_type": "Compound",
          "entity_name": "retinoic acid",
          "context": "retinoic acid, and estrogen-related receptors"
        },
        {
          "entity_type": "Compound",
          "entity_name": "estrogen",
          "context": "estrogen-related receptors"
        }
      ]
    },
    {
      "chunk_id": "f8827a5be1922ae284df7420ee7df3bf",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "MAO-B inhibitors",
          "context": "including MAO-B inhibitors"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO substrates",
          "context": "and the MAO substrates PEA and DA"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PEA",
          "context": "the MAO substrates PEA"
        },
        {
          "entity_type": "Compound",
          "entity_name": "DA",
          "context": "and DA"
        },
        {
          "entity_type": "Disease",
          "entity_name": "neuropsychiatric disorders",
          "context": "phenotypes of neuropsychiatric disorders"
        }
      ]
    },
    {
      "chunk_id": "0c20e5394d74690d25026b86002eaa0c",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "MAO",
          "context": "Modification of MAO expression"
        }
      ]
    },
    {
      "chunk_id": "8d9cc0fc7426db2dd41f38ec08f3b309",
      "entities": [
        {
          "entity_type": "Effect",
          "entity_name": "stress response",
          "context": "associated with stress response"
        },
        {
          "entity_type": "Effect",
          "entity_name": "cell-cycle arrest",
          "context": "cell-cycle arrest"
        },
        {
          "entity_type": "Effect",
          "entity_name": "cell survival",
          "context": "and cell survival"
        },
        {
          "entity_type": "Effect",
          "entity_name": "anti-oxidative",
          "context": "involved in anti-oxidative"
        },
        {
          "entity_type": "Effect",
          "entity_name": "pro-survival",
          "context": "and pro-survival functions"
        },
        {
          "entity_type": "Compound",
          "entity_name": "valproic acid",
          "context": "by valproic acid"
        },
        {
          "entity_type": "Compound",
          "entity_name": "VPA",
          "context": "VPA, 2-propylpentanoic acid"
        },
        {
          "entity_type": "Compound",
          "entity_name": "2-propylpentanoic acid",
          "context": "VPA, 2-propylpentanoic acid"
        }
      ]
    },
    {
      "chunk_id": "5ccd440e44c5b4b599d041dafa0bc08c",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "miRNAs",
          "context": "miRNAs regulate gene expression"
        },
        {
          "entity_type": "Compound",
          "entity_name": "mRNAs",
          "context": "target mRNAs"
        },
        {
          "entity_type": "Effect",
          "entity_name": "down-regulate expression",
          "context": "down-regulate expression by binding"
        },
        {
          "entity_type": "Compound",
          "entity_name": "precursor miRNAs",
          "context": "longer precursor miRNAs"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Drosa",
          "context": "enzymes, Drosa and Dicer"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Dicer",
          "context": "enzymes, Drosa and Dicer"
        },
        {
          "entity_type": "Compound",
          "entity_name": "RNAs",
          "context": "functional RNAs of ~22 nucleotides"
        },
        {
          "entity_type": "Compound",
          "entity_name": "RNA-inducing silencing complex",
          "context": "an RNA-inducing silencing complex"
        },
        {
          "entity_type": "Effect",
          "entity_name": "suppresses translation",
          "context": "complex that suppresses translation"
        },
        {
          "entity_type": "Compound",
          "entity_name": "miR-9",
          "context": "brain-specific miRNAs, miR-9"
        },
        {
          "entity_type": "Compound",
          "entity_name": "miR-124",
          "context": "miR-9, -124 and -134"
        },
        {
          "entity_type": "Compound",
          "entity_name": "miR-134",
          "context": "miR-9, -124 and -134"
        },
        {
          "entity_type": "Compound",
          "entity_name": "miR-133b",
          "context": "miRNA, miR-133b"
        },
        {
          "entity_type": "Effect",
          "entity_name": "reduced miR-133b levels",
          "context": "Dicer knockdown reduced miR-133b levels"
        },
        {
          "entity_type": "Disease",
          "entity_name": "PD-like phenotype",
          "context": "development of a PD-like phenotype"
        },
        {
          "entity_type": "Effect",
          "entity_name": "down-regulated",
          "context": "miR-133b expression was down-regulated"
        },
        {
          "entity_type": "Disease",
          "entity_name": "PD",
          "context": "down-regulated in PD brains"
        },
        {
          "entity_type": "Disease",
          "entity_name": "neurodegenerative disorders",
          "context": "other neurodegenerative disorders"
        },
        {
          "entity_type": "Disease",
          "entity_name": "panic disorder",
          "context": "respect to panic disorder"
        },
        {
          "entity_type": "Disease",
          "entity_name": "anxiety",
          "context": "in anxiety patients"
        },
        {
          "entity_type": "Compound",
          "entity_name": "miR-22",
          "context": "anxiety patients, miR-22"
        },
        {
          "entity_type": "Compound",
          "entity_name": "miR-138-2",
          "context": "miR-22, -138-2, -148a and -488"
        },
        {
          "entity_type": "Compound",
          "entity_name": "miR-148a",
          "context": "miR-22, -138-2, -148a and -488"
        },
        {
          "entity_type": "Compound",
          "entity_name": "miR-488",
          "context": "miR-22, -138-2, -148a and -488"
        },
        {
          "entity_type": "Effect",
          "entity_name": "regulate several candidate anxiety genes",
          "context": "found to regulate several candidate anxiety genes"
        },
        {
          "entity_type": "Compound",
          "entity_name": "mao-a",
          "context": "regulated mao-a gene expression"
        },
        {
          "entity_type": "Effect",
          "entity_name": "regulated mao-a gene expression",
          "context": "miR-22 regulated mao-a gene expression"
        },
        {
          "entity_type": "Disease",
          "entity_name": "HIV encephalitis",
          "context": "human HIV encephalitis"
        },
        {
          "entity_type": "Compound",
          "entity_name": "miR-142",
          "context": "neuronal species miR-142"
        },
        {
          "entity_type": "Effect",
          "entity_name": "increased",
          "context": "miR-142 were increased"
        },
        {
          "entity_type": "Effect",
          "entity_name": "overexpression",
          "context": "Its overexpression in a human neuron cell line"
        },
        {
          "entity_type": "Effect",
          "entity_name": "down-regulated",
          "context": "cell line down-regulated"
        }
      ]
    },
    {
      "chunk_id": "03797b614ace9baf8ac009ef89cfbf59",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "Sirt1",
          "context": "Sirt1, and also decreased MAO-A mRNA"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO-A mRNA",
          "context": "decreased MAO-A mRNA, protein and enzyme activity levels"
        },
        {
          "entity_type": "Compound",
          "entity_name": "protein",
          "context": "MAO-A mRNA, protein and enzyme activity levels"
        },
        {
          "entity_type": "Compound",
          "entity_name": "enzyme",
          "context": "protein and enzyme activity levels"
        },
        {
          "entity_type": "Effect",
          "entity_name": "decreased ... activity levels",
          "context": "decreased MAO-A mRNA, protein and enzyme activity levels"
        },
        {
          "entity_type": "Compound",
          "entity_name": "miR-142",
          "context": "regulation of MAO-A expression by the miR-142-Sirt1-MAO-A pathway"
        },
        {
          "entity_type": "Effect",
          "entity_name": "regulation of ... expression",
          "context": "regulation of MAO-A expression by the miR-142-Sirt1-MAO-A pathway"
        },
        {
          "entity_type": "Compound",
          "entity_name": "DA",
          "context": "changes in DA transmission"
        },
        {
          "entity_type": "Effect",
          "entity_name": "changes in ... transmission",
          "context": "changes in DA transmission"
        },
        {
          "entity_type": "Disease",
          "entity_name": "HIV-associated neurocognitive disorders",
          "context": "in HIV-associated neurocognitive disorders"
        }
      ]
    },
    {
      "chunk_id": "b3b0887b79eb97b0356749a59bc179c5",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "Monoamine oxidase",
          "context": "Monoamine oxidase plays a major role"
        },
        {
          "entity_type": "Compound",
          "entity_name": "monoamine transmitters",
          "context": "metabolism of monoamine transmitters"
        },
        {
          "entity_type": "Effect",
          "entity_name": "metabolism",
          "context": "role in the metabolism"
        },
        {
          "entity_type": "Compound",
          "entity_name": "ROS",
          "context": "generation of ROS"
        },
        {
          "entity_type": "Compound",
          "entity_name": "neurotoxins",
          "context": "generation of ROS and neurotoxins"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO-A",
          "context": "MAO-A expression and activity"
        },
        {
          "entity_type": "Disease",
          "entity_name": "apoptosis",
          "context": "increased in apoptosis"
        },
        {
          "entity_type": "Effect",
          "entity_name": "oxidative stress",
          "context": "via oxidative stress"
        },
        {
          "entity_type": "Effect",
          "entity_name": "mitochondrial dysfunction",
          "context": "and mitochondrial dysfunction"
        },
        {
          "entity_type": "Effect",
          "entity_name": "pro-survival genes",
          "context": "induction of pro-survival genes"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MPP+",
          "context": "neurotoxins, such as MPP+"
        },
        {
          "entity_type": "Compound",
          "entity_name": "N-methyl(R)salinol",
          "context": "and N-methyl(R)salinol"
        },
        {
          "entity_type": "Effect",
          "entity_name": "mitochondrial permeability",
          "context": "increases mitochondrial permeability"
        },
        {
          "entity_type": "Effect",
          "entity_name": "anti-apoptotic",
          "context": "the anti-apoptotic Bcl-2 protein family"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Bcl-2 protein family",
          "context": "anti-apoptotic Bcl-2 protein family"
        },
        {
          "entity_type": "Compound",
          "entity_name": "rasagiline",
          "context": "by rasagiline is mediated by MAO-A"
        },
        {
          "entity_type": "Effect",
          "entity_name": "knockdown",
          "context": "consequences of MAO-A knockdown"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO-B",
          "context": "in MAO-B-expressing Caco-2"
        }
      ]
    },
    {
      "chunk_id": "87d6ab7bf2b37cefc4bbbcae31b6d7c3",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "MAO-A",
          "context": "induction of MAO-A expression"
        },
        {
          "entity_type": "Effect",
          "entity_name": "neuronal survival",
          "context": "determining neuronal survival"
        },
        {
          "entity_type": "Effect",
          "entity_name": "pro-survival genes",
          "context": "induction of pro-survival genes"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MAO-B inhibitors",
          "context": "genes by MAO-B inhibitors"
        },
        {
          "entity_type": "Compound",
          "entity_name": "selegiline",
          "context": "binding site(s) of selegiline"
        },
        {
          "entity_type": "Compound",
          "entity_name": "rasagiline",
          "context": "and rasagiline on MAO-A"
        },
        {
          "entity_type": "Effect",
          "entity_name": "gene induction",
          "context": "respect to gene induction"
        },
        {
          "entity_type": "Effect",
          "entity_name": "neuronal death signal pathways",
          "context": "modulate neuronal death signal pathways"
        },
        {
          "entity_type": "Effect",
          "entity_name": "CNS function",
          "context": "sustaining CNS function"
        }
      ]
    },
    {
      "chunk_id": "4215ed5dbcef2e19e90a70aec6da81df",
      "entities": [
        {
          "entity_type": "Disease",
          "entity_name": "Neurodegeneration",
          "context": "Verein zur Erforschung von Neurodegeneration, Neuroprotektion, Neuroregeneration und Therapie e. V."
        }
      ]
    }
  ],
  "total_entities": 441,
  "extraction_date": "2026-02-01T08:37:31.673963+00:00"
}